Related Experiment Video
Updated: Sep 23, 2026
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Clinical implications of vasoactive intestinal peptide and 5-hydroxytryptamine in diabetic neurogenic bladder and
Long Shi1, Shaoqi Zhang1, Longjun Cai1
1The Affiliated Suqian Hospital of Xuzhou Medical University, Department of Urinary Surgery, Suqian, Jiangsu, China.
Background:
To elucidate the clinical significance of vasoactive intestinal peptide (VIP) and 5-hydroxytryptamine (5-HT) in diabetic neurogenic bladder (DNB). We aimed to determine the diagnostic, stratifying, and prognostic value of their simultaneous detection, and to reveal the dynamic associations of these biomarkers with post-void residual urine volume (PVR).
Methods:
The study population consisted of 30 DNB patients and 30 healthy individuals from the same timeframe (June 2024-April 2025). Laboratory assessments quantified serum VIP concentration by enzyme-linked immunosorbent assay (ELISA) and 5-HT concentration by liquid chromatography-mass spectrometry (LC-MS). PVR quantification relied on urodynamic examination and abdominal ultrasound. Over a 3-month follow-up, serial measurements of VIP and 5-HT were obtained. Statistical analyses, including Pearson correlation, receiver operating characteristic (ROC) curve analysis, and logistic regression modeling, were employed to assess the relationships of these biomarkers with PVR, bladder function classification, and patient prognosis.
Results:
Significant reductions in VIP and 5-HT were observed in DNB patients relative to controls (P< 0.05). The combined use of VIP and 5-HT achieved an area under the curve (AUC) value of 0.878, with 83.33% sensitivity and 86.67% specificity, indicating better diagnostic efficacy than single-marker detection (P< 0.05). VIP and 5-HT levels were inversely related to PVR (P< 0.05). In DNB patients, both biomarkers increased gradually at one and three months post-treatment (P< 0.05), paralleling urodynamic improvements. Stratification by bladder dysfunction severity (mild, moderate, severe) revealed a progressive decline in VIP and 5-HT levels with increasing severity (P < 0 .0 5), confirming their utility in disease staging. Patients with lower VIP and 5-HT levels three months after treatment had a greater propensity for upper urinary tract impairment, urinary tract infections, and disease advancement.
Conclusions:
The combined detection of VIP and 5-HT enables effective evaluation of DNB severity, forecasts disease progression, and offers a foundation for timely intervention through dynamic monitoring.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
01:22Diabetes Insipidus II: Pathophysiology
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:29Diabetes Insipidus I: Introduction
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:26The Micturition Reflex
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating urine...